Pharma News

The Chilean health ministry has confirmed the first case of sexually transmitted Zika virus in the country, the media reported on Sunday.The 46-year-old woman was infected with the virus as she had unprotected sex with her partner, who was infected with Zika in Haiti, said the ministry on Saturday.

Pregnant women with higher blood levels of a common plastic chemical used in the coatings of food containers are more likely to deliver their babies early compared with women with lower levels of that chemical, says a study led by an Indian-origin researcher.

Turmeric, an essential ingredient that spices up an Indian curry, may help fight drug-resistant tuberculosis, new research has found.

A cancer treatment through Yoga that does away with the need for chemotherapy to arrest and cure the disease is just a year away, union Minister of state for AYUSH Shripad Naik said on Saturday.

Aiming to slash the prevalence of violence-borne diarrhoea, the health ministry on Saturday launched the Rota Virus vaccine here, which will be available free of cost at public healthcare facilities, initially in four states.

We are often ignorant about loss of teeth but preserving oral health can benefit you in a longer run. According to researchers, loss of teeth is linked to increased risk for cognitive impairment and dementia in adults.

What has brain to do with glucose metabolism? A lot, say researchers, suggesting that not just your pancreas, a group of neurons in the hypothalamus area also plays a vital role in maintaining blood glucose levels.

[adsense:336x280:8701650588]

Asia's premier biopharmaceutical company, today announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved its biosimilar Insulin Glargine.  This is a significant achievement for Biocon and its commercial partner, FUJIFILM Pharma Co. Ltd (FFP) as it endorses our endeavor to bring high quality, yet affordable, world class products to diabetes patients in Japan.

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Taltz should not be used in patients with a previous hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. Taltz is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.

Pfizer Inc. announced  that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ® (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA.